

## Vaccine Access Update

Senate Committee on Early Childhood and Behavioral Health

Dr. Sejal Hathi, MD, MBA, Oregon Health Authority Director

Dr. Dean Sidelinger, MD, State Epidemiologist and Health Officer

# What is happening? Federal action and inaction have caused significant confusion regarding vaccine policy



#### May 2025

HHS Secretary Kennedy removed recommendations for COVID-19 vaccination in pregnancy and healthy children from CDC immunization schedules

 Neither ACIP nor CDC subject matter experts were consulted



#### **July 2025**

Kennedy terminated all ACIP liaisons from medical and public health institutions citing influence from special interest groups

Kennedy terminated all 17 members of ACIP citing conflicts of interest and has since appointed 12 new members, including several prominent vaccine skeptics

**June 2025** 

FDA revoked all COVID-19 vaccine EUAs and restricted approval for all four COVID-19 vaccine products to adults 65+ and younger individuals with underlying medical conditions



Aug. 2025

## The results

### Restricted access to the COVID-19 vaccine

- Pharmacies required prescriptions or attestation of underlying medical conditions for the updated COVID-19 vaccine due to the narrow FDA approval language and absence of 2025-26 ACIP recommendations
- Providers and pharmacies reluctant to stock the 2025-26 COVID-19 vaccine

## Provider confusion

## Consumer confusion

## Oregon responds: The West Coast Health Alliance

- Oregon, Washington, California, and Hawaii have issued evidence-based immunization <u>recommendations</u> informed by respected, national medical organizations
- Goals
  - Provide evidence-based vaccine recommendations
  - Ensure continued access to vaccines at low or no cost

#### Consensus WCHA 2025-26 Respiratory Season Immunization Recommendations **COVID-19 vaccine** Influenza vaccine RSV immunization All ≥ 6 months All < 8 months<sup>1</sup> Children All 6-23 months All 2-17 years with risk factors • All 8-19 months All with close contact with others with risk with risk factors<sup>1</sup> factors All who choose protection 32-36 weeks Pregnancy All planning, pregnant, postpartum, and All planning, lactating gestational age<sup>1</sup> pregnant, postpartum, and lactating Adults All ≥ 65 years All ≥ 18 years All ≥ 75 years All 50-74 years All 18-64 years with risk factors All with close contact with others with risk with risk factors factors All who choose protection

<sup>&</sup>lt;sup>1</sup>Either immunization with nirsevimab/clesrovimab or maternal RSV vaccination is indicated to protect infants from severe RSV infection.

## Oregon responds: Multi-agency effort

## OHA manages response efforts and coordinates with:

- Department of Consumer and Business Services
- Board of Pharmacy
- State Board of Nursing
- Oregon Medical Board

### **Agency actions**

- Policy changes to make WCHA-recommended vaccines easily accessible, covered by insurance
- Communications through multiple channels to boost provider and consumer confidence



(Enter) DEPARTMENT (ALL CAPS) (Enter) Division or Office (Mixed Case)



## **ACIP Meeting Updates**

# The September 18-19 ACIP meeting included MMRV, hepatitis B, and COVID-19 vaccine votes

- MMRV: adopted recommendation against MMRV vaccine in children under 4 due to risk of febrile seizure and voted for adoption of resolution to VFC
  - Impact: VFC theoretically will no longer cover MMRV in children under 4, however, this level of detail is
    not typically provided to VFC; uncertain if coverage will change at this time
     N.B. MMRV is used in 15% of first doses; separate MMR and varicella vaccines are available
- **Hepatitis B**: vote has been tabled; anticipate next vote on hepatitis B vaccine will include more restrictive language regarding age of first dose (> 2, 6 months, or even 12 years)
  - Impact: coverage will not change at this time
- COVID-19: adopted three recommendations: (1) for additional and controversial language to be added to VIS; (2) that informed consent should occur prior to vaccination; and (3) that COVID-19 vaccines be recommended in alignment with FDA approval (65 and older, 6 months 64 years risk-based)
  - **Impacts**: (1) biased and inaccurate language may reduce vaccine uptake; (2) no impact, this is standard of care; (3) coverage will not change at this time

## What's next?

- Continue monitoring federal action on vaccines
  - Await CDC action on September 18-19 ACIP votes
  - The next ACIP meeting is scheduled for October 22-23
  - Explore long-term policy options

## Thank you

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact Em Droge at emily.droge@oha.oregon.gov or at 971-409-3449. We accept all relay calls.



## **Acronyms**

- ACIP Advisory Committee on Immunization Practices
- CDC Centers for Disease Control and Prevention
- EUA Emergency Use Authorization
- FDA Food and Drug Administration
- MMRV Measles, Mumps, Rubella, Varicella vaccine
- RSV Respiratory Syncytial Virus
- VFC Vaccines for Children program
- WCHA West Coast Health Alliance